Barinthus Biotherapeutics plc (BRNS)

Market Cap	44.65M
Revenue (ttm)	14.97M
Net Income (ttm)	-57.83M
Shares Out	40.23M
EPS (ttm)	-1.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,446
Open	1.020
Previous Close	1.060
Day's Range	1.020 - 1.112
52-Week Range	0.801 - 4.159
Beta	-0.72
Analysts	Strong Buy
Price Target	4.00 (+260.36%)
Earnings Date	Nov 6, 2024

About BRNS

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company’s development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human p...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2021
• Employees: 130
• Stock Exchange: NASDAQ
• Ticker Symbol: BRNS
• Website: https://www.barinthusbio.com

Analyst Forecast

According to 2 analysts, the average rating for BRNS stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 260.36% from the latest price.

Price Target

$4.0

(260.36% upside)

Analyst Consensus: Strong Buy